Bowel Diseases, Inflammatory Clinical Trial
Official title:
A 2-Cohort Study to Evaluate the Absolute Bioavailability, Absorption, Distribution, Metabolism and Excretion of TD-1473 Following an Intravenous and an Oral Dose of [14C]-TD-1473 in Healthy Male Subjects
Verified date | January 2021 |
Source | Theravance Biopharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label, 2-cohort study to evaluate the absolute bioavailability, absorption, distribution, metabolism and excretion of TD-1473 in healthy male subjects. Subjects in cohort 1 will receive a single oral dose of TD-1473 and a single intravenous bolus dose of [14C]-TD-1473. Subjects in cohort 2 will receive a single oral dose of [14C]-TD-1473 only.
Status | Completed |
Enrollment | 20 |
Est. completion date | February 21, 2018 |
Est. primary completion date | February 21, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 19 Years to 55 Years |
Eligibility | Inclusion Criteria: - Subject is a healthy, nonsmoking male, 19 to 55 years old, inclusive - Subject has a body mass index (BMI) 19 to 32 kg/m2, inclusive, and weighs at least 50 kg - Subject is healthy as determined by the PI or designee based on medical history and physical examination performed at Screening and Day -1 - Additional inclusion criteria apply Exclusion Criteria: - Subject has any condition possibly affecting drug absorption (e.g., previous surgery on the gastrointestinal tract [including removal of parts of the stomach, bowel, liver, gall bladder, or pancreas]) - Subject has a known hypersensitivity towards medications similar to TD 1473 or excipients contained in TD 1473 - Subject regularly works with ionizing radiation or radioactive material - Subject has been exposed to ionizing radiations, within 1 year prior to the start of the study, as external irradiation (i.e., radiological examination including CT scan, excluding dental radiography) or internal radiation (i.e., diagnostic nuclear medicine procedure) or have participated in a radiolabeled study in the last 12 months - Subject, who, for any reason, is deemed by the PI or designee or Sponsor to be inappropriate for this study or have any condition which would confound or interfere with the evaluation of the safety, tolerability, and PK of the investigational drug or prevent compliance with the study protocol - Additional exclusion criteria apply |
Country | Name | City | State |
---|---|---|---|
United States | Celerion | Lincoln | Nebraska |
Lead Sponsor | Collaborator |
---|---|
Theravance Biopharma |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Metabolites in Plasma | TD 1473 metabolite profiling will be performed in plasma containing sufficient amounts of radioactivity | Up to 15 days | |
Other | Metabolites in Urine | TD 1473 metabolite profiling will be performed in urine containing sufficient amounts of radioactivity | Up to 15 days | |
Other | Metabolites in Feces | TD-1473 metabolite profiling will be performed in feces containing sufficient amounts of radioactivity | Up to 15 days | |
Primary | Maximum observed concentration (Cmax) in Plasma | Up to 15 days | ||
Primary | Time to maximum observed concentration (tmax) in Plasma | Up to 15 days | ||
Primary | Area under the concentration-time curve from hour 0 to the last measurable concentration (AUC0-last) in Plasma | Up to 15 days | ||
Primary | Area under the concentration-time curve extrapolated to infinity (AUC0-inf) in Plasma | Up to 15 days | ||
Primary | Apparent terminal elimination half-life (t1/2) in Plasma | Up to 15 days | ||
Primary | Apparent clearance (Cl/F) in Plasma | Up to 15 days | ||
Primary | Apparent volume of distribution (Vz/F) in Plasma | Up to 15 days | ||
Primary | Absolute bioavailability (%F) in Plasma | Up to 15 days | ||
Secondary | Amount excreted in urine (Aeu) over the sampling interval in Urine | Up to 15 days | ||
Secondary | Renal clearance (CLr) in Urine | Up to 15 days | ||
Secondary | The percent excreted in urine (%Feu) in Urine | Up to 15 days | ||
Secondary | Amount excreted in feces (Aef) over the sampling interval in Feces | Up to 15 days | ||
Secondary | The percent excreted in feces (%Fef) | Up to 15 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00640809 -
Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole
|
Phase 4 | |
Completed |
NCT04587713 -
Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects
|
Phase 1 | |
Completed |
NCT05043363 -
LuCID - Investigating the Use of a Novel Digital Rectoscope for Community Examinations During COVID-19
|
||
Completed |
NCT02799615 -
Anti-TNF Therapy for Refractory Colitis in Hospitalized Children
|
||
Not yet recruiting |
NCT02760940 -
Anemia in Inflammatory Bowel Disease
|
Phase 4 | |
Terminated |
NCT04032756 -
Tofacitinib Registry of Patients With Ulcerative Colitis in Germany
|
||
Terminated |
NCT02255227 -
Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD
|
Phase 2 | |
Completed |
NCT03999294 -
Bmgim Music Therapy Method in Reducing Stress in Patients With Inflammatory Bowel Disease
|
N/A |